Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

35.96USD
22 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$35.96
Open
--
Day's High
--
Day's Low
--
Volume
101
Avg. Vol
18,882,092
52-wk High
$36.21
52-wk Low
$29.83

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $214,146.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.56

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

FRANKFURT European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.

Sep 21 2017

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

FRANKFURT, Sept 21 European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.

Sep 21 2017

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Sep 20 2017

UPDATE 3-Pfizer files suit against J&J over Remicade contracts

Sept 20 Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Sep 20 2017

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Sep 20 2017

Pfizer sues Johnson & Johnson over Remicade biosimilar

Sept 20 Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying that the drugmaker's anticompetitive contracts with health insurers prevented biosimilar competition to its blockbuster rheumatoid arthritis drug, Remicade.

Sep 20 2017

BRIEF-‍Pfizer files lawsuit against Johnson & Johnson​

* ‍Pfizer says filed suit in U.S. District Court for Eastern District of Pennsylvania against Johnson & Johnson​

Sep 20 2017

BRIEF-Pfizer announces outcome of FDA advisory committee meeting for Sutent

* Pfizer announces outcome of FDA advisory committee meeting for Sutent in patients at high risk of recurrent renal cell carcinoma after surgery

Sep 19 2017

Pfizer, Astellas prostate cancer drug promising in late-stage trial

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

Sep 14 2017

UPDATE 3-Pfizer, Astellas prostate cancer drug promising in late-stage trial

* Pfizer's shares up 1.8 pct (Adds analysts' comments, details on drug's potential market; updates shares)

Sep 14 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.39 --
Novartis AG (NOVN.S) CHF83.65 +0.20
Merck & Co., Inc. (MRK.N) $65.13 --
Roche Holding Ltd. (ROG.S) CHF249.10 +1.10
Roche Holding Ltd. (RO.S) CHF249.30 +1.30
Abbott Laboratories (ABT.N) $52.51 --
Bayer AG (BAYGn.DE) €111.90 +1.80
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €84.46 +0.34
AstraZeneca plc (AZN.L) 4,926.50 +14.50

Earnings vs. Estimates